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SHORT COMMUNICATION
Tumour promotors but not initiators deplete Langerhans cells from
murine epidermis
G.M. Halliday, G.R. Mac Carrick & H.K. Muller
Department ofPathology, University of Tasmania, GPO Box 252C, Hobart, Australia 7001.
Langerhans cells (LC) are an essential component of
cutaneous immunological defence mechanisms (Halliday &
Muller, 1984). They are bone-marrow derived cells (Stingl et
al., 1980), which in the epidermis form a continuous network
of cells linked to each other via their dendritic processes
(Halliday et al., 1986). The role of this network is unknown,
but it presumably aids the trapping of foreign antigens as
these cells have been demonstrated to bind epidermal
antigens (Shelley & Juhlin, 1977). Following antigen-binding
LC migrate via dermal lymphatics to the local lymph nodes
where they function as antigen-presenting cells, thereby initi-
ating an immune response against the antigen (Silberberg-
Sinakin & Thorbecke, 1980; Streilein & Bergstresser, 1980;
Stingl et al., 1978).
Since LC link the epidermis to the systemic immune
system, they may be an important component of immuno-
logical defence against skin tumours. Recent observations of
increased numbers of LC in human skin tumours (McArdle
et al., 1986) support such a role for LC. We have also
demonstrated that the chemical carcinogen 7,12-dimethyl-
benz(a)anthracene (DMBA) depletes LC from mouse skin
during the period while tumours became macroscopically
visible (Muller et al., 1985). In these experiments some of the
tumours regressed as the LC repopulated the epidermis.
Some chemical carcinogens induce tumour growth by
themselves e.g. DMBA, whereas there are other chemicals
which are not complete carcinogens, and these have been
divided functionally into initiators and promotors. The two-
stage model of carcinogenesis where treatment with both an
initiator and a promoter are required to induce tumour
growth has been reviewed by Slaga (1984). The initiation
phase is an irreversible event, requiring a single application
of the initiator, while promotion is reversible, with repeated
treatments required, which may be delayed for up to one
year following initiation (Slaga, 1984). In this investigation,
the two-stage model of carcinogenesis in mouse skin has
been utilized to further define the role of LC in
carcinogenesis.
BALB/c mice were treated with either 1, 2, or 3 weekly
topical applications of 20,i1 promotor or initiator to the
dorsal surface of each ear. The promotors assessed were
0.1% croton oil (Sigma, Lot 43F-0415; Roe & Peirce, 1961);
0.005% 12-0-tetradecanoylphorbol 13-acetate (TPA, Sigma,
Lot 34F-0682; Verma et al., 1978); and 0.005% teleocidin (a
gift from Dr Fujiki; Fujiki & Sugimura, 1983), the vehicle in
each case being acetone. The initiators used were 10%
urethane (Sigma, Lot 102F-0300) in acetone (Graffi et al.,
1953); 0.5% chrysene (Sigma, Lot 84F-3597) in equal parts
of lanoline and liquid paraffin (Scribner, 1973); and 0.25%
benz(a)anthracene (Sigma, Lot 129C-0520) in acetone
(Scribner, 1973). Controls were treated with acetone alone.
One week following the final treatment, mice were killed
by cervical dislocation and their ears were excised for LC
quantitation in epidermal sheets by adenosine triphosphatase
(ATPase) staining as described previously (Halliday et al.,
1986). LC were visualised by light microscopy, and the
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numbers present in 6 fields were counted for each ear per
mouse. The size of the field was determined using a
graticule, and the number of LC mm-2 of epidermis calcu-
lated for each mouse. A total area of 8.15mm2 was counted
per mouse.
By light microscopy, LC were observed in the epidermis of
control BALB/c mouse ears as brown ATPase-positive cells
linked to each other via dendritic processes. The LC density
was within the range 345-534 cells per mm2, which is similar
to that previously observed in the dorsal trunk of this mouse
strain (Muller et al., 1985). There was no difference in LC
density between the control group of mice treated with
solvent for I week, and the groups treated with the tumour
initiators urethane, chrysene, or benz(a)anthracene for 1
week (Table I). The initiators also did not alter LC mor-
phology. In contrast, all of the tumour promotors assessed,
croton oil, TPA, and teleocidin, consistently depleted LC
from the epidermis, as shown by the significantly lower LC
in treated compared to control groups. Increased exposure to
the initiators urethane, chrysene and benz(a)anthracene for 2
or 3 consecutive weeks still did not cause any alteration in
the number or morphology of ATPase-positive LC; in
contrast the tumour promotors croton oil, TPA, and teleo-
cidin significantly decreased the LC to levels which were
similar to those observed after treatment for 1 week (Table
I). The tumour initiators examined have no promotor
activity (Slaga et al., 1982), and were used at concentrations
which have previously been shown to be effective in the two
stage model of tumour-induction (Graffi et al., 1953;
Scribner, 1973). Thus LC are affected by tumour promotors,
but not initiators.
LC were also identified using a Philips 410 electron
microscope based on their well characterised ultrastructure
and presence of the unique Birbeck granule (Birbeck et al.,
1961). LC were frequently observed in control, urethane,
chrysene and benz(a)anthracene-treated epidermis. These
initiators did not discernibly alter LC ultrastructure. In
contrast, LC were difficult to find in promotor-treated skin;
e.g. in one specimen only a single LC was observed in the
epidermis of a croton oil-treated mouse, and this showed no
features of ultrastructural damage. It has been demonstrated
by electron microscopy that under some circumstances the
ATPase marker may be modulated from the LC plasma
membrane without depleting the cells from the epidermis
(Aberer et al., 1981). However, electronmicroscopic examin-
ation of promotor and initiator-treated skin confirmed our
results obtained by ATPase staining, indicating that the
tumour promotors had not modulated ATPase from the LC
surface, but had depleted these cells from the epidermis.
LC took more than 6 weeks to return to control values
after croton oil treatment (Table II) which is similar to the 8
week time period we have previously observed for LC
repopulation of DMBA-treated epidermis (Muller et al.,
1985). This long recovery time provides further support that
promotors deplete LC from the epidermis rather than
modulating ATPase from the plasma membrane.
Fiurstenberger et al. (1983) found that the critical effects of
tumour promotors last for at least 2 months in mouse
epidermis. As this is similar to the time LC remain depleted
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Table I Langerhans cell densities' in murine epidermis treated weekly with tumour promoters or initiators
I Week 2 Weeks 3 Weeks
Mean Langerhans Mean Langerhans Mean Langerhans
Treatment cells mm-2 cells mm-2 cells mm-2
ofmice (range) PC n (range) PC n (range) PC n
Controlb 386 (350-415) - 8 385 (345-435) - 8 422 (345-530) - 8
Promotors:
croton oil 123 (60-235) <0.01 6 146 (110-190) <0.01 6 132 (105-165) <0.01 6
TPA 179 (140-195) <0.01 6 140 (105-230) <0.01 6 157 (125-200) <0.01 6
teleocidin 156 (120-215) <0.01 6 129 (110-160) <0.01 6 116 (50-175) <0.01 6
Initiators:
urethane 380 (310-465) NS 6 384 (355-460) NS 6 399 (450-495) NS 6
chrysene 395 (355-440) NS 6 426 (350-550) NS 6 450 (365-560) NS 6
benz(a)anthracene 394 (335-425) NS 6 453 (395-550) NS 6 486 (335-570) NS 6
aDetermined by staining for ATPase; bTreated with acetone alone; cStatistical comparison with controls (unpaired Wilcoxon rank sum
test; Sokal & Rohlf, 1969); NS: not significant; n: number of mice in group.
Table II Langerhans cell repopulation following
depletion by 3 weekly treatments with croton oil
Time since Mean Langerhans
final croton cells mm-2
oil treatment (range)a. pb n
1 week 137 (89-179) <0.005 6
3 weeks 231 (179-264) <0.005 5
6 weeks 271 (237-293) <0.005 6
Controlsc 323 (285-384) - 6
aDetermined by staining for ATPase; bStatistical
comparison with controls (unpaired Wilcoxon rank
sum test; Sokal & Rohlf, 1969); cTreated with acetone
alone; n: number of mice in group.
following croton oil treatment, LC depletion may be one of
the critical steps in tumour promotion.
Croton oil, the first tumour promotor to be discovered
(Berenblum, 1941), has been thoroughly investigated and
found to be a strong promotor with very little, if any,
initiating potential (Klein-Szanto, 1984). It is however a
multicomponent mixture of lipids, of which a series of eleven
phorbol diesters have been found to be active tumour
promotors (Hecker, 1968). The most potent tumour
promotor of these phorbol diesters, TPA, was observed to
deplete LC from the epidermis in the present study. As
croton oil and TPA depleted LC to similar levels (p not
significant) it is likely that the croton oil-mediated depletion
of LC was caused by TPA in the croton oil. However a
cumulative effect involving the other active phorbol diesters
cannot be excluded. Teleocidin, an indole alkaloid, is
structurally unrelated to TPA, but is a potent tumour
promotor which lacks initiator activity (Fujiki & Sugimura,
1983). As these chemically unrelated promotors have similar
effects on LC, LC-depletion may be a general step in the
process of tumour promotion in the skin.
The tumour promotor-induced depletion of LC demon-
strated in this study has important implications for under-
standing the process of tumour growth. LC are an essential
component of cutaneous immunological defence mechanisms
(Halliday & Muller, 1984), and therefore any potential
tumour cells may be inhibited from growing into a tumour
by the LC presenting tumour-associated-antigens to T cells,
thus indLucing an anti-tumour immune response. Depletion of
LC by a promotor might enable potential tumour cells to
grow into a tumour unhindered by an immune response. We
have previously shown that sensitization of mice with di-
nitrofluorobenzene through skin depleted of LC by treat-
ment with the complete carcinogen DMBA activates specific
suppressor T lymphocytes which inhibit subsequent attempts
to induce immunity against this antigen (Halliday & Muller,
1986). Hence, upon recovery of LC from the effects of
tumour promotors, they may be unable to activate immune
defence mechanisms due to the presence of specific
suppressor T cells.
Electronmicroscopy failed to reveal any degenerating LC
in tumour promotor-treated skin. Therefore, it is likely that
tumour promotors do not destroy LC but induce their
migration from the epidermis. TPA has been shown to
activate other cells of the immune system; it modulates the
T4 antigen from T lymphocytes (Solbach, 1982), collaborates
with anti-T3 antibodies to cause activation and proliferation
of T lymphocytes (Hara & Fu, 1985), and can substitute for
macrophages during mitogen activation of T lymphocytes
(Rosenstreich & Mizel, 1979). Likewise, tumour promotors
may activate LC to migrate from the epidermis.
It is concluded that while transformed cells may be
inhibited from growing into a tumour by an immune
response mounted against tumour-associated-antigens
presented via LC to T lymphocytes, depletion of the LC by
promotors would abrogate this response, thus enabling the
transformed cell to grow unhindered. However, this may not
be the only effect of tumour promotors on anti-tumour
immunity as TPA has also been shown to suppress macro-
phage and NK cell tumour cytotoxicity (Keller, 1979). In
contrast to our findings with tumour promotors, tumour
initiators had no effect on LC. Whether alteration of local
antigen-presenting cells occurs in other models of chemical
carcinogenesis which involve multiple steps, such as in the
liver (Farber, 1984), is unknown, but such an investigation
would determine if this is a requirement for tumour growth
at other sites.
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